XML 73 R57.htm IDEA: XBRL DOCUMENT
v3.21.2

Licenses and collaborative arrangement (Details) $ / shares in Units, $ in Thousands |  | 1 Months Ended | 3 Months Ended | 6 Months Ended
--- | --- | --- | --- | ---
Jan. 13, 2021 $ / shares shares | Jan. 31, 2021 USD ($) | Dec. 31, 2020 $ / shares | Jun. 30, 2019 Milestone | Dec. 31, 2017 Investors | Mar. 31, 2021 USD ($) | Jun. 30, 2021 USD ($) Milestone programs Molecules $ / shares
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Common stock par value | $ / shares |  |  | $ 0.00006 |  |  |  | $ 0.00006
Issuance of ordinary shares in connection with collaboration and license arrangement |  |  |  |  |  | $ 62,250 |
Number of molecules | Molecules |  |  |  |  |  |  | 2
Number of programs | programs |  |  |  |  |  |  | 4
Maximum |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Future milestone payments to be made upon achievement |  |  |  |  |  |  | $ 4,541,502
Five Prime |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
License agreement date |  |  |  |  | 2017-12 |  |
Payment of upfront fees |  |  |  |  |  |  | 5,000
Number of milestone payments | Investors |  |  |  |  | 1 |  |
Milestone payments |  |  |  |  |  |  | 2,000
Five Prime | Maximum |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Additional milestone payments |  |  |  |  |  |  | 37,000
Deciphera Pharmaceuticals LLC |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
License agreement date |  |  |  | 2019-06 |  |  |
Payment of upfront fees |  |  |  |  |  |  | 20,000
Milestone payment accrued |  |  |  |  |  | $ 12,000 |
Number of milestone payments | Milestone |  |  |  | 3 |  |  |
Deciphera Pharmaceuticals LLC | Maximum |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Additional milestone payments |  |  |  |  |  |  | 173,000
Argenx BV |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
License agreement date |  | 2021-01 |  |  |  |  |
Development cost-sharing payment |  |  |  |  |  |  | 75,000
Issuance of ordinary shares in connection with collaboration and license arrangement, Shares | shares | 568,182 |  |  |  |  |  |
Common stock par value | $ / shares | $ 0.00006 |  |  |  |  |  |
Issuance of ordinary shares in connection with collaboration and license arrangement |  |  |  |  |  |  | 62,250
Future cash payment |  |  |  |  |  |  | 25,000
GSK |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Payment of upfront fees |  |  |  |  |  |  | 15,000
Milestone payment accrued |  |  |  |  |  |  | $ 3,500
Number of milestone payments Accrued | Milestone |  |  |  |  |  |  | 1
Number of milestone payments | Milestone |  |  |  |  |  |  | 1,000,000
Milestone payments |  |  |  |  |  |  | $ 1,000
Additional milestone payments |  |  |  |  |  |  | 36,000,000
ZLAB Turning Point Therapeutics Inc |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Milestone payment accrued |  |  |  |  |  |  | $ 3,000
Number of milestone payments Accrued | Milestone |  |  |  |  |  |  | 2
Number of milestone payments | Milestone |  |  |  |  |  |  | 1
Milestone payments |  |  |  |  |  |  | $ 2,000
Mirati Therapeutics Inc |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Payment of upfront fees for license agreement, accrued |  |  |  |  |  |  | 65,000
Future milestone payments to be made upon achievement |  |  |  |  |  |  | $ 273,000
Mirati Therapeutics Inc | Maximum |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Percentage of tiered royalties on annual net sales |  |  |  |  |  |  | 20.00%
Mirati Therapeutics Inc | Minimum |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Percentage of tiered royalties on annual net sales |  |  |  |  |  |  | 0.00%
MacroGenics |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Payment of upfront fees |  |  |  |  |  |  | $ 25,000
Payment of upfront fees for license agreement, accrued |  |  |  |  |  |  | $ 25,000
Number of milestone payments | Milestone |  |  |  |  |  |  | 2
Milestone payments |  |  |  |  |  |  | $ 4,000
Additional milestone payments |  |  |  |  |  |  | 136,000
Future milestone payments to be made upon achievement |  |  |  |  |  |  | 1,386,000
MacroGenics | Collaboration and License Agreement [Member] |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Equity Method Investments |  |  |  |  |  |  | $ 30,000
Issue price per share | $ / shares |  |  |  |  |  |  | $ 31.30
Turning Point Therapeutics Inc |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
License agreement date |  | 2021-01 |  |  |  |  | 2020-07
Payment of upfront fees |  | $ 25,000 |  |  |  |  | $ 25,000
Turning Point Therapeutics Inc | Potential Development Regulatory and Sales Based Milestone |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Additional milestone payments |  | $ 336,000 |  |  |  |  |
Future milestone payments to be made upon achievement |  |  |  |  |  |  | 146,000
Cullinan Pearl Corp |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
License agreement date |  |  | 2020-12 |  |  |  |
Payment of upfront fees |  |  |  |  |  |  | 20,000
Cullinan Pearl Corp | Potential Development Regulatory and Sales Based Milestone |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Future milestone payments to be made upon achievement |  |  |  |  |  |  | 211,000
Takeda Pharmaceutical Company Limited |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
License agreement date |  |  | 2020-12 |  |  |  |
Payment of upfront fees |  |  |  |  |  |  | 6,000
Takeda Pharmaceutical Company Limited | Potential Development Regulatory and Sales Based Milestone |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Future milestone payments to be made upon achievement |  |  |  |  |  |  | $ 481,500

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Face amount or stated value per share of common stock. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_CommonStockParOrStatedValuePerShare
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.12) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_EquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Per share or per unit amount of equity securities issued. + References No definition available. + Details
Name: | us-gaap_SharesIssuedPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP). + References No definition available. + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP). + References No definition available. + Details
Name: | us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount represents the additional milestone payments. + References No definition available. + Details
Name: | zlab_AdditionalMilestonePayments
Namespace Prefix: | zlab_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Development cost sharing payment. + References No definition available. + Details
Name: | zlab_DevelopmentCostSharingPayment
Namespace Prefix: | zlab_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Future cash payment. + References No definition available. + Details
Name: | zlab_FutureCashPayment
Namespace Prefix: | zlab_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Future contingent milestone payments to be made upon achievement. + References No definition available. + Details
Name: | zlab_FutureContingentMilestonePaymentsToBeMadeUponAchievement
Namespace Prefix: | zlab_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition License agreement date and year. + References No definition available. + Details
Name: | zlab_LicenseAgreementDateAndYear
Namespace Prefix: | zlab_
Data Type: | xbrli:gYearMonthItemType
Balance Type: | na
Period Type: | duration

X
- Definition Milestone payment accrued. + References No definition available. + Details
Name: | zlab_MilestonePaymentAccrued
Namespace Prefix: | zlab_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount represents milestone payments. + References No definition available. + Details
Name: | zlab_MilestonePayments
Namespace Prefix: | zlab_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of milestone payments. + References No definition available. + Details
Name: | zlab_NumberOfMilestonePayments
Namespace Prefix: | zlab_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number Of Milestone Payments Accrued. + References No definition available. + Details
Name: | zlab_NumberOfMilestonePaymentsAccrued
Namespace Prefix: | zlab_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number Of Molecules. + References No definition available. + Details
Name: | zlab_NumberOfMolecules
Namespace Prefix: | zlab_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of programs. + References No definition available. + Details
Name: | zlab_NumberOfPrograms
Namespace Prefix: | zlab_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Payment of upfront fees for license agreement. + References No definition available. + Details
Name: | zlab_PaymentOfUpFrontFeesForLicenseAgreement
Namespace Prefix: | zlab_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage of Tiered Royalties on Annual Net sales. + References No definition available. + Details
Name: | zlab_PercentageOfTieredRoyaltiesOnAnnualNetSales
Namespace Prefix: | zlab_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Up Front Fees For License Agreement Accrued. + References No definition available. + Details
Name: | zlab_UpFrontFeesForLicenseAgreementAccrued
Namespace Prefix: | zlab_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=zlab_FivePrimeTherapeuticsIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=zlab_DecipheraPharmaceuticalsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=zlab_ArgenxBvMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=zlab_GskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=zlab_ZlabTurningPointTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=zlab_MiratiTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=zlab_MacroGenicsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | zlab_AgreementAxis=zlab_CollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=zlab_TurningPointTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | zlab_MilestoneAxis=zlab_PotentialDevelopmentRegulatoryAndSalesBasedMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=zlab_CullinanPearlCorpMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=zlab_TakedaPharmaceuticalCompanyLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |